Alterity Therapeutics to Present at MST Financial Webinar
Ticker: PRNAF · Form: 6-K · Filed: Jul 24, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: presentation, company-update
TL;DR
ALT to present at MST webinar, check for updates.
AI Summary
Alterity Therapeutics Limited announced on July 24, 2024, that it will present at the MST Financial Webinar. The company is a development stage enterprise focused on pharmaceutical preparations.
Why It Matters
This presentation provides an opportunity for investors and the public to learn more about Alterity Therapeutics' progress and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a presentation and does not contain significant financial or operational news.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- MST Financial Webinar (company) — Event
- PRANA BIOTECHNOLOGY LTD (company) — Former Company Name
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 and Form F-3.
What is the primary business of Alterity Therapeutics Limited?
Alterity Therapeutics Limited is a development stage enterprise in the Pharmaceutical Preparations industry.
When was Alterity Therapeutics Limited previously known as?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD.
What specific event is Alterity Therapeutics Limited announcing?
Alterity Therapeutics Limited is announcing its participation in a presentation at the MST Financial Webinar.
Where is Alterity Therapeutics Limited's principal executive office located?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-07-24 08:00:02
Filing Documents
- ea0209931-6k_alterity.htm (6-K) — 13KB
- ea020993101ex99-1_alterity.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-063754.txt ( ) — 28KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics to Present at MST Financial Webinar 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: July 24, 2024 2